Loading
A phase 1/2 trial of ruxolitinib and retifanlimab in lung cancer, run by University of California, San Diego, now recruiting.
Retifanlimab and Ruxolitinib In Solid Malignancies is a phase 1/2, interventional study registered as NCT07219576 by University of California, San Diego, with a registry enrolment figure of 40 participants, started 2026-01-08 and due to reach its primary completion in 2027-12. Interventions recorded: Ruxolitinib; Retifanlimab. Conditions listed: Non Small Cell Lung Carcinoma; Renal Cell Carcinoma. Primary outcome: Recommended phase 2 dose. Lung eligibility wording from the registry: "Advanced or metastatic clear cell renal cell carcinoma or non-small cell lung carcinoma having progressed on prior PD-1/PD-L1 therapy (radiographic progression within 6 months of discontinuing immunotherapy; immunotherapy does not need to be the immediate line of preceding therapy)". Sites: United States. No results are recorded here; the registry entry is the source.
Shares Lung cancer trials open today (registry snapshot), Immune checkpoint inhibitors, Non-small-cell lung cancer and the tag lung-deep-dive.
Shares Lung cancer trials open today (registry snapshot), Immune checkpoint inhibitors, Non-small-cell lung cancer and the tag lung-deep-dive.
Shares Lung cancer trials open today (registry snapshot), Immune checkpoint inhibitors, Non-small-cell lung cancer and the tag lung-deep-dive.
Shares Lung cancer trials open today (registry snapshot), Immune checkpoint inhibitors, Non-small-cell lung cancer and the tag lung-deep-dive.
Shares Lung cancer trials open today (registry snapshot), Immune checkpoint inhibitors, Non-small-cell lung cancer and the tag lung-deep-dive.
Shares Lung cancer trials open today (registry snapshot), Immune checkpoint inhibitors, Non-small-cell lung cancer and the tag lung-deep-dive.
Shares Lung cancer trials open today (registry snapshot), Non-small-cell lung cancer and the tag lung-deep-dive.
Shares Lung cancer trials open today (registry snapshot), Non-small-cell lung cancer and the tag lung-deep-dive.